AstraZeneca to showcase new data on type-2 diabetes and cardiorenal complications

Image of a laptop with medication, health charts and other symbols to show AstraZeneca to showcase new data on type-2 diabetes and cardiorenal complications

AstraZeneca is to showcase leadership in treating type-2 diabetes and cardiorenal complications at ADA 2020.

It will present new data from the landmark Phase III DAPA-HF and DECLARE-TIMI 58 trials at the upcoming 80th American Diabetes Association (ADA) Virtual Scientific Sessions, 12-16 June 2020. The data are among 23 accepted abstracts, including four oral presentations, covering trials that showcase the depth and breadth of potential cardio, renal and metabolic benefits for patients across AstraZeneca’s portfolio.

Highlights include:

  • An oral presentation of data from the DAPA-HF trial showing the effect of Farxiga (dapagliflozin) on the incidence of new onset of type-2 diabetes (T2D) in patients with heart failure and reduced ejection fraction (HFrEF) (Abstract #271-OR).
  • New sub analyses from the DECLARE-TIMI 58 trial, presented orally, providing insights on Farxiga’s effect on fast kidney function decline in T2D patients with established or increased risk for cardiovascular disease (Abstract #303-OR).
  • An analysis of the DAPA-HF trial examining if background T2D therapy impacts the benefits of Farxiga in heart failure (HF) (Abstract #1112-P).
  • A new analysis of the global observational DISCOVER real world evidence study, presented orally, reporting health-related quality of life factors in patients with T2D initiating a 2nd-line glucose-lowering therapy (Abstract #40-OR).
  • An oral presentation of new Phase II data on investigational cotadutide, a dual receptor agonist with balanced GLP-1 and glucagon activity, showing positive effect on blood glucose levels and changes in liver fat and glycogen stores in patients with T2D (Abstract #354-OR).
  • Brilinta (ticagrelor) data on duration of T2D, baseline HbA1c levels as well as the impact of blood sugar-lowering background therapies on outcomes in T2D patients with coronary artery disease (THEMIS diabetes subgroup) (Abstract #403-P).

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: “An overwhelming majority of people with type-2 diabetes also have at least one other cardiovascular, renal or metabolic disease. The breadth and depth of data we are presenting at ADA 2020 demonstrates our commitment to developing treatment options for patients living with diabetes that go beyond glycaemic control to also protect the heart, liver and kidneys.”

In addition to its robust clinical data, AstraZeneca will also present results from a global survey of more than 1,600 physicians in 18 countries examining primary care approaches and clinical inertia in the treatment of patients with T2D.